Ji Pharmaceutical Holdings intends to acquire a 100% stake in Amended Pharmaceuticals, Jilin's richest man or shell listing

Pharmaceutical Holdings announced on the evening of July 10 that it intends to purchase a 100% stake in Amended Pharmaceutical Group Co., Ltd. through the issuance of shares. The transaction is expected to constitute a major asset restructuring and the company will be suspended from trading on July 11.
Correction pharmaceutical industry or shell listingcorrective pharmaceutical industry official website shows that the company's chairman Xiu Yugui founded, is concentrated in pharmaceutical, chemical pharmaceutical, biopharmaceutical research and production marketing, drug chain management, Traditional Chinese medicine standard cultivation in one of the large-scale modern private pharmaceutical enterprises.
As early as 2015, the pharmaceutical industry realized output value of 58.8 billion yuan, sales revenue of 57.5 billion yuan, profits and taxes of 4 billion yuan, while in 2016 achieved total industrial output value of 64.6 billion yuan, sales revenue of 63.6 billion yuan, profits and taxes of 4.76 billion yuan.
The controlling shareholders of Correctional Pharmaceuticals are Tonghua Correctional Industrial Co., Ltd., with a 70% shareholding ratio, while Shu Yugui, Li Yanhua, Wang Huayu and Chen Liancheng hold 29.518 percent, 0.4 percent, 0.06 percent and 0.022 percent, respectively. Xiu Yugui, Li Yan Huawei husband and wife relationship, for many years in a row the first place in Jilin rich list, with "the richest in Jilin Province" said. Industry and commerce data show that Xiu Yugui and Li Yanhua hold 98% and 2% of the shares of Tonghua CorrectionAlide Industrial Co., Ltd., respectively.

it is understood that the pharmaceutical industry as early as more than a decade ago had plans to go public. Prior to this, there were a variety of plates circulating in the market regarding the revision of pharmaceutical listings, such as A-share listings, Hong Kong listings, IPOs, shell listings and so on. However, no substantial progress was made until Ji Pharmaceutical Holdings disclosed its proposed acquisition of Amended Pharmaceuticals.
As of July 10, the total share capital of Ji Pharmaceutical Holdings was 660 million shares, with a total market value of 3.6 billion yuan. Last year, Ji Pharmaceutical Holdings' revenue and net profit were 942 million yuan and 217 million yuan, respectively, with assets of 5,063 million yuan at the end of the first quarter of this year. By contrast, the pharmaceutical industry is relatively large, and the deal could constitute a restructuring listing.
Jilin state-owned to terminate thejiji pharmaceutical holding predecessor is Ssanlong shares, is the domestic fixed-point production of national defense chemical industry precipitation white carbon black enterprises. In 2014, Ssinglong shares through the issuance of shares and cash to buy a 97.71% stake in Jinbao Pharmaceuticals, the opportunity to enter the pharmaceutical sector, began from the chemical industry to the pharmaceutical industry turn around. In 2017, a listed company that has changed its name from Ssinglong to Ji Pharmaceutical Holdings took the remaining 2.29% of Jinbao Pharmaceuticals, a deal that was completed in December 2017.
In recent years, Ji Pharmaceutical Holdings has taken the pharmaceutical industry (including Chinese and Western traditional medicine, API, biopharmaceuticals), pharmaceutical commercial (wholesale services), pharmaceutical terminal chain and medical and medical industry as the strategic positioning of the company's development, and has continuously carried out foreign mergers and acquisitions.
In January 2018, Ji Pharmaceutical Holdings increased its capital to Haitong Pharmaceuticals, investing 67.0625 million yuan and holding a 10% stake in Haitong Pharmaceuticals; In September, Ji Pharmaceutical Holdings announced the acquisition of a 70% stake in Liaoning Merro Pharmaceutical Supply Co., Ltd. for 28 million yuan in cash, and in September 2018, announced that it intends to pay cash to buy 99.68 percent of PricePay's shares held by 46 natural persons, including Yang Hua, with a provisional bid of 618 million yuan.
After a series of outward acquisitions, and as many focused on what other extended expansions Gidding Holdings would have in the future, Jipantr Holdings disclosed the proposed change of control in May.
On May 17, 2019, the controlling shareholders of Ji pharmaceutical holdings, Lu Zhongkui and Huang Kefeng, Sun Jun, who own more than 5%, and Meihekou Jinhede Venture Capital Center (Limited Partnership), signed the Agreement of Intent on Share Transfer with Jisheng Capital Management, Lu Zhongkui and Huang Mr. and Mrs. Kefeng, Sun Jun and shareholder Mei Estuar Jinhede Venture Capital Center (Limited Partnership) agreed to transfer part of their shares to Jisheng Capital Management, respectively, in accordance with the agreement, with a total of 101 million shares to be transferred, accounting for 15.18% of the total share capital.
Upon completion of the share transfer, Mr. and Mrs. Lu Zhongkui and Mr. Huang Kefeng intend to transfer 95,163,000 shares of the remaining shares, accounting for 14.29% of the total share capital of Ji pharmaceutical holdings (including the shares increased by the above-mentioned shares as a result of the rights issue, share transfer, share transfer, etc.) corresponding to the voting rights, nomination and proposal rights, participation rights, supervisory advice rights and other rights in addition to income rights, share transfer and pledge guarantee.
Jisheng Capital Management is a wholly state-owned enterprise with 100% ownership of SASAC in Jilin Province, if the transfer of shares is finally completed, the controlling shareholder of Jisheng Holdings will become Jisheng Capital Management, and the actual controller will be changed to SASAC of Jilin Province.
On the evening of July 10th, The Company disclosed that it had decided to terminate the deal because the two sides had not reached an agreement. (
Securities Times
)